This study examined the effect of androgen deprivation therapy (ADT) on clinical depression. Authors reported that ADT increased the risk of depression and the need for psychiatric treatment. The risk of depression increased with duration of ADT.

This study compared the effect of two chemotherapy drugs used in the treatment of metastatic prostate cancer. Survival rates and pain relief were compared with cabazitaxel (jevtana) or mitoxantrone (novantrone) therapy.

This study compared the benefit of combining different local therapies with hormone therapy for metastatic prostate cancer. Researchers reported a survival benefit for patients treated with surgery or intensity modulated radiation therapy (a type of radiation therapy) before hormone therapy.

This study evaluated the potential of surgical margins in predicting biochemical recurrence in patients with localized prostate cancer.

This study examined the efficacy of two different types of radiation therapies among patients with localized (confined) prostate cancer. 

The authors aimed to determine the change in bone density in patients who received luteinizing hormone-releasing agonists (LHRHa, treatments that reduce testosterone production in the body) compared to estradiol patches (patches that deliver the hormone estradiol).

The authors concluded that EPs reduce the loss of bone density and significantly reduce the level of testosterone in the patient.

This review compared the potential risks and benefits of two hormone therapies available for androgen deprivation therapy (ADT). Authors concluded that GnRH antagonists offer a safe and effective alternative to GnRH agonists.

This study compared early metabolic changes across different types of androgen deprivation therapy (ADT). Authors reported that some metabolic changes were more pronounced with pharmacological ADT compared to surgical ADT.